Joint Ministry Initiative to Address Gender Dysphoria in Minors: Evidence-Based Guidelines for Triptorelin Use.

Schillaci and Roccella Collaborating on New guidelines for Triptorelin Dysphoria

The Ministry of Health and the Ministry of Family have joined forces to address the controversial issue of gender dysphoria in minors. Specifically, they are focusing on the use of triptorelin, a puberty blocking drug. This joint initiative is being led by Ministers Orazio Schillaci and Eugenia Roccella.

To develop new guidelines based on scientific literature and experiences from other countries, a table of technicians and experts is being formed. The composition of this table will be finalized in the near future.

The two ministries have released a joint statement summarizing their work so far on gender dysphoria and the use of blockers. They mention that this initiative follows a hearing with scientific societies involved in the issue of gender dysphoria in adolescents and a request made to the National Bioethics Committee to reevaluate the use of triptorelin in cases of dysphoria in minors. In addition, they are conducting a survey among regions regarding clinical monitoring, expenditures, and prescriptions of triptorelin for cases of dysphoria, and have requested a report from AIFA on the therapeutic indications for the drug.

This collaborative effort represents a proactive approach to addressing the complex issue of gender dysphoria in minors. The focus is on evidence-based guidelines and best practices, with updates provided as new specific guidelines are developed for this important issue.

Leave a Reply